SWOG clinical trial number
S9622

Evaluation of CI-980 in Patients with Disseminated Malignant Melanoma and No Prior Chemotherapy, Phase II

Closed
Phase
Accrual
55%
Published
Abbreviated Title
Evaluation of CI-980 in Patients with Disseminated Malignant Melanoma and No Prior Chemotherapy, Phase II
Activated
12/15/1996
Closed
08/01/1998

Research committees

Melanoma

Publication Information Expand/Collapse

2008

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]

EL Korn;PY Liu;SJ Lee;JAW Chapman;D Niedzwiecki;VJ Suman;J Moon;VK Sondak;MB Atkins;EA Eisenhauer;W Parulekar;SN Markovic;S Saxman;JM Kirkwood Journal of Clinical Oncology 26(4):527-534

2001

Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy: a Southwest Oncology Group Study

RP Whitehead;JM Unger;LE Flaherty;JR Eckardt;SA Taylor;MS Didolkar;W Samlowski;VK Sondak Investigational New Drugs 19:239-243

1999

Phase II trial of CI-980 in patients with disseminated malignant melanoma: A Southwest Oncology Group Study.

RP Whitehead;JM Unger;LE Flaherty;JR Eckardt;SA Taylor;MS Didolkar;W Samlowski;VK Sondak Proc of the American Society of Clinical Oncology 18:554(#2138)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6134

A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
Research Committee(s)
Melanoma
Activated
07/13/2015
Open
Phase